Coherus Biosciences price target lowered by $2 at H.C. Wainwright, here's whyThe Fly • 27 days ago
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Share to Feed
Investors eyeing a purchase of Coherus BioSciences Inc (CHRS) shares, but cautious about paying the going market price of 2.37/share, might benefit from considering selling puts among the...
Related Stocks: NAS:CHRS...
Company Focuses on Oncology and Launches New Products Amidst RestructuringRelated Stocks: CHRS...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Net revenue of $91.5 million in the fourth quarter and $257.2 million in FY 2023 UDENYCA net sales of $36.2 million in the fourth quarter and $127.1 million in FY 2023 CIMERLI net...
REDWOOD CITY, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. ( Coherus, NASDAQ: CHRS) today announced that its fourth quarter and full year 2023 financial results will be...
Upfront cash payment of $170 million strengthens capital structure Transaction solidifies Coherus' strategic focus in oncology REDWOOD CITY, Calif., March 04, 2024 (GLOBE NEWSWIRE...
REDWOOD CITY, Calif., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. ( Coherus or the Company , Nasdaq: CHRS), today announced that effective February 20, 2024, the compensation...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...